{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:17:34Z","timestamp":1775845054593,"version":"3.50.1"},"reference-count":50,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Opioid-induced constipation (OIC) may occur in patients receiving opioid treatment, decreasing their quality of life (QOL). We compared the effectiveness of magnesium oxide (MgO) with that of naldemedine (NAL) in preventing OIC. This proof-of-concept, randomized controlled trial (registration number UMIN000031891) involved 120 patients with cancer scheduled to receive opioid therapy. The patients were randomly assigned and stratified by age and sex to receive MgO (500 mg, thrice daily) or NAL (0.2 mg, once daily) for 12 weeks. The change in the average Japanese version of Patient Assessment of Constipation QOL (JPAC-QOL) from baseline to 2 weeks was assessed as the primary endpoint. The other endpoints were spontaneous bowel movements (SBMs) and complete SBMs (CSBMs). Deterioration in the mean JPAC-QOL was significantly lower in the NAL group than in the MgO group after 2 weeks. There were fewer adverse events in the NAL group than in the MgO group. Neither significant differences in the change in SBMs between the groups nor serious adverse events\/deaths were observed. The CSBM rate was higher in the NAL group than in the MgO group at 2 and 12 weeks. In conclusion, NAL significantly prevented deterioration in constipation-specific QOL and CSBM rate compared with MgO.<\/jats:p>","DOI":"10.3390\/cancers14092112","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T22:22:41Z","timestamp":1650838961000},"page":"2112","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial"],"prefix":"10.3390","volume":"14","author":[{"given":"Anna","family":"Ozaki","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-1386","authenticated-orcid":false,"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuma","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Iwaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7240-4851","authenticated-orcid":false,"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8839-9594","authenticated-orcid":false,"given":"Takayuki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, International University of Health and Welfare Atami Hospital, Atami 413-0012, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-3057","authenticated-orcid":false,"given":"Akihiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Fuyuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"},{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1931-6326","authenticated-orcid":false,"given":"Kento","family":"Imajo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-4396","authenticated-orcid":false,"given":"Takuma","family":"Higurashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[{"name":"Department of Data Science, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0800-2161","authenticated-orcid":false,"given":"Hiroto","family":"Ishiki","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Yokohama City University Hospital, Yokohama 236-0004, Japan"},{"name":"Department of Oncology, Yokohama City University Hospital, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-1436","authenticated-orcid":false,"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2013.52.5188","article-title":"Principles of Opioid Use in Cancer Pain","volume":"32","author":"Portenoy","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of Opioid Analgesics in the Treatment of Cancer Pain: Evidence-Based Recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1756283X15589526","article-title":"Evolving Paradigms in the Treatment of Opioid-Induced Bowel Dysfunction","volume":"8","author":"Poulsen","year":"2015","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-014-0254-6","article-title":"Quality of Life and Healthcare Resource in Patients Receiving Opioids for Chronic Pain: A Review of the Place of Oxycodone\/Naloxone","volume":"35","author":"Morlion","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.2147\/DDDT.S92998","article-title":"Efficacy and Tolerability of Oral Oxycodone and Oxycodone\/Naloxone Combination in Opioid-Naive Cancer Patients: A Propensity Analysis","volume":"9","author":"Lazzari","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ajg.2011.30","article-title":"Opioid-Induced Constipation: Challenges and Therapeutic Opportunities","volume":"106","author":"Camilleri","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejpain.2008.09.005","article-title":"Gastrointestinal Symptoms under Opioid Therapy: A Prospective Comparison of Oral Sustained-Release Hydromorphone, Transdermal Fentanyl, and Transdermal Buprenorphine","volume":"13","author":"Wirz","year":"2009","journal-title":"Eur. J. Pain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","article-title":"Gastrointestinal Side Effects in Chronic Opioid Users: Results from a Population-Based Survey","volume":"27","author":"Cook","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/jpm.2009.0355","article-title":"Reduction of Opioid Side Effects by Prophylactic Measures of Palliative Care Team May Result in Improved Quality of Life","volume":"13","author":"Myotoku","year":"2010","journal-title":"J. Palliat. Med."},{"key":"ref_11","first-page":"1045","article-title":"Opioid-Related Bowel Dysfunction: Prevalence and Identification of Predictive Factors in a Large Sample of Italian Patients on Chronic Treatment","volume":"14","author":"Rosti","year":"2010","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1002\/cam4.2341","article-title":"Incidence of Opioid-Induced Constipation in Japanese Patients with Cancer Pain: A Prospective Observational Cohort Study","volume":"8","author":"Tokoro","year":"2019","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2982.2009.01458.x","article-title":"Opioid-Induced Bowel Disorders and Narcotic Bowel Syndrome in Patients with Chronic Non-Cancer Pain","volume":"22","author":"Tuteja","year":"2010","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11938-016-0112-0","article-title":"Opioids and Gi Motility-Friend or Foe?","volume":"14","author":"Lee","year":"2016","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_15","unstructured":"Japanese Society of Palliative Medicine, and Committee on Guidelines (2017). Guidelines for the Palliation of Gastrointestinal Symptoms in Cancer Patients 2017 Edition, Japanese Society for Palliative Medicine. Published Online."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/AJP.0b013e318237d626","article-title":"A Multi-Institutional Study Analyzing Effect of Prophylactic Medication for Prevention of Opioid-Induced Gastrointestinal Dysfunction","volume":"28","author":"Ishihara","year":"2012","journal-title":"Clin. J. Pain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/nmo.12417","article-title":"Emerging Treatments in Neurogastroenterology: A Multidisciplinary Working Group Consensus Statement on Opioid-Induced Constipation","volume":"26","author":"Camilleri","year":"2014","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/cpdd.387","article-title":"Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies on the Safety, Tolerability, and Pharmacokinetics of Naldemedine in Healthy Volunteers","volume":"7","author":"Fukumura","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/pm\/pnw325","article-title":"A phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain","volume":"18","author":"Webster","year":"2017","journal-title":"Pain Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17512433.2019.1570845","article-title":"A Meta-Analysis of Naldemedine for the Treatment of Opioid-Induced Constipation","volume":"12","author":"Song","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13063-020-04385-0","article-title":"Comparing the Effectiveness of Magnesium Oxide and Naldemedine in Preventing Opioid-Induced Constipation: A Proof of Concept, Single Institutional, Two Arm, Open-Label, Phase II, Randomized Controlled Trial: The MAGNET Study","volume":"21","author":"Ozaki","year":"2020","journal-title":"Trials"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00535-013-0825-y","article-title":"Validity and Reliability of the Japanese Version of the Patient Assessment of Constipation Quality of Life Questionnaire","volume":"49","author":"Nomura","year":"2014","journal-title":"J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","article-title":"Randomized phase III and Extension Studies: Efficacy and Impacts on Quality of Life of Naldemedine in Subjects with Opioid-Induced Constipation and Cancer","volume":"29","author":"Katakami","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and Efficacy of Elobixibat for Chronic Constipation: Results from a Randomised, Double-Blind, Placebo-Controlled, phase 3 Trial and an Open-Label, Single-Arm, phase 3 Trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and Validation of the Patient Assessment of Constipation Quality of Life Questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/003655299750025327","article-title":"Psychometric Validation of a Constipation Symptom Assessment Questionnaire","volume":"34","author":"Frank","year":"1999","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional Bowel Disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF02056950","article-title":"A Constipation Scoring System to Simplify Evaluation and Management of Constipated Patients","volume":"39","author":"Agachan","year":"1996","journal-title":"Dis. Colon Rectum"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel Disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, Adaptation, and Validation of the SF-36 Health Survey for Use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ajg.2010.41","article-title":"Multicenter, 4-Week, Double-Blind, Randomized, Placebo-Controlled Trial of Sodium Picosulfate in Patients with Chronic Constipation","volume":"105","author":"Kamm","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_33","unstructured":"European Medicines Agency (2015). Guideline on the Evaluation of Medicinal Products for the Treatment of Chronic Constipation (Including Opioid Induced Constipation) and for Bowel Cleansing, European Medicines Agency and Committee for Medicinal Products for Human Use (CHMP)."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3177\/jnsv.53.30","article-title":"Food Intake and Functional Constipation: A Cross-Sectional Study of 3,835 Japanese Women Aged 18\u201320 Years","volume":"53","author":"Murakami","year":"2007","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2169\/internalmedicine.4399-19","article-title":"The Association Between Frailty and Abdominal Symptoms: A Hospital-Based Cross-Sectional Study","volume":"59","author":"Asaoka","year":"2020","journal-title":"Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/13543784.2011.563236","article-title":"Naloxone as Part of a Prolonged Release Oxycodone\/Naloxone Combination Reduces Oxycodone-Induced Slowing of Gastrointestinal Transit in Healthy Volunteers","volume":"20","author":"Smith","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.bpg.2020.101691","article-title":"An Overview of Acute Gastrointestinal Side Effects of Systemic Anti-Cancer Therapy and Their Management","volume":"48\u201349","author":"Smith","year":"2020","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrgastro.2013.18","article-title":"New Perspectives in the Diagnosis and Management of Enteric Neuropathies","volume":"10","author":"Knowles","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"G223","DOI":"10.1152\/ajpgi.00212.2014","article-title":"Platinum-Based Chemotherapy: Gastrointestinal Immunomodulation and Enteric Nervous System Toxicity","volume":"308","author":"Stojanovska","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","article-title":"FDA Approval Summary: Atezolizumab plus Paclitaxel Protein-Bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1","volume":"26","author":"Narayan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-015-3652-4","article-title":"Effects of a Self-Management Program on Antiemetic-Induced Constipation During Chemotherapy Among Breast Cancer Patients: A Randomized Controlled Clinical Trial","volume":"155","author":"Hanai","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Chemotherapy-Induced Diarrhea: Pathophysiology, Frequency and Guideline-Based Management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved Prevention of Moderately Emetogenic Chemotherapy-Induced Nausea and Vomiting with Palonosetron, a Pharmacologically novel 5-HT3 Receptor Antagonist: Results of a phase III, Single-Dose Trial Versus Dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2013.08.049","article-title":"Molecular Mechanisms of 5-HT(3) and NK(1) Receptor Antagonists in Prevention of Emesis","volume":"722","author":"Rojas","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(01)01297-3","article-title":"Effects of CP-99, 994, a Tachykinin NK(1) Receptor Antagonist, on Abdominal Afferent Vagal Activity in Ferrets: Evidence for Involvement of NK(1) and 5-HT(3) Receptors","volume":"428","author":"Minami","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"118048","DOI":"10.1016\/j.lfs.2020.118048","article-title":"Preventive Effects of Naldemedine, Peripherally Acting Mu-Opioid Receptor Antagonist, on Morphine-Induced Nausea and Vomiting in Ferrets","volume":"257","author":"Kanemasa","year":"2020","journal-title":"Life Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00520-019-04884-0","article-title":"A Preliminary Study of the Effect of Naldemedine Tosylate on Opioid-Induced Nausea and Vomiting","volume":"28","author":"Sato","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bjd.12235","article-title":"Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study","volume":"168","author":"Gisondi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_50","unstructured":"(2014). Clinical Guidelines for Cancer Pain Management, WHO. [2nd ed.]."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2112\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:59:41Z","timestamp":1760137181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092112"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092112","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,24]]}}}